CRISPR Therapeutics sets IPO terms

Gene editing company CRISPR Therapeutics AG (Basel, Switzerland) plans to sell 4.7 million shares at $15-$17 in an IPO on NASDAQ underwritten by Citigroup, Piper Jaffray, Barclays and Guggenheim. At $16, the company would raise $75.2 million and be valued at $636 million.

CRISPR Therapeutics would be the third CRISPR company to go public, behind Editas Medicine Inc. (NASDAQ:EDIT) and Intellia Therapeutics Inc. (NASDAQ:NTLA). Its most advanced programs are focused on ex vivo approaches for hemoglobinopathies. ...